10x Genomics, Inc. (TXG)
| Market Cap | 6.61B |
| Revenue (ttm) | 590.98M |
| Net Income (ttm) | -223.36M |
| Shares Out | 118.21M |
| EPS (ttm) | -1.91 |
| PE Ratio | n/a |
| Forward PE | 196.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 494,507 |
| Open | 57.21 |
| Previous Close | 57.55 |
| Day's Range | 55.53 - 57.78 |
| 52-Week Range | 33.79 - 63.57 |
| Beta | 1.88 |
| Analysts | Buy |
| Price Target | 59.09 (+5.59%) |
| Earnings Date | Feb 14, 2024 |
About TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for me... [Read more]
Financial Performance
In 2022, 10x Genomics's revenue was $516.41 million, an increase of 5.28% compared to the previous year's $490.49 million. Losses were -$166.00 million, 185.1% more than in 2021.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for TXG stock is "Buy." The 12-month stock price forecast is $59.09, which is an increase of 5.59% from the latest price.
News
10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PLEASANTON, Calif. , Dec. 21, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will present at th...
10x Genomics Launches Xenium Catalyst Network
Founding Network Members Will Accelerate Access to Proof-of-Concept Data for Prospective Xenium Customers Worldwide PLEASANTON, Calif. , Dec. 20, 2023 /PRNewswire/ -- 10x Genomics, Inc. , (Nasdaq: TX...
Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness
A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platforms PLEASANTON, Calif. , Dec. 19, 2023 /PRNew...
High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint
Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif. , Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: ...
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
PLEASANTON, Calif. , Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alz...
NanoString stock sinks nearly 50% after losing patent lawsuit case against 10x Genomics
Shares of Seattle-based publicly traded biotech company NanoString Technologies fell nearly 50% to an all-time low on Monday following its loss in a patent infringement case against 10x Genomics.
10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies
Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing Serial ...
OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
PLEASANTON, Calif. and PARIS , Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell t...
10x Genomics Reports Third Quarter 2023 Financial Results
PLEASANTON, Calif. , Nov. 2, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September ...
10x Genomics to Present at the Stephens 25th Annual Conference
PLEASANTON, Calif. , Nov. 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in...
Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors
Scientific pre-print featuring customer-generated data demonstrates the power of single cell spatial analysis to more directly assess unique tissue microenvironments and cell-cell interactions PLEASAN...
10x Genomics to Report Third Quarter 2023 Financial Results on November 2, 2023
PLEASANTON, Calif. , Oct. 11, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the third quarter...
10x Genomics Comments on Second UPC Preliminary Injunction Decision
UPC Denies Second Preliminary Injunction Request; Prior Injunctions Against NanoString's CosMx Products in Europe Remain in Full Effect PLEASANTON, Calif. , Oct. 10, 2023 /PRNewswire/ -- 10x Genomics,...
10x Wins Injunction From Unified Patent Court Banning Sales of NanoString's CosMx Products in Europe
Second Injunction Issued Against CosMx PLEASANTON, Calif. , Sept. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the Europ...
10x Genomics Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit
Strengthen cellular analysis with cost-efficient multiomic readouts and streamlined workflows PLEASANTON, Calif. , Sept. 14, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single c...
Study Enabled by 10x Genomics Single Cell and Spatial Technologies Explains Why Immunotherapy is More Effective for Certain Brain Tumors Than Others
Researchers uncover mechanisms behind divergent responses to immune checkpoint blockade between primary and metastatic brain tumors PLEASANTON, Calif. , Sept. 5, 2023 /PRNewswire/ -- 10x Genomics , In...
10x Genomics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PLEASANTON, Calif. , Aug. 30, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate i...
10x Genomics Surpasses 100 Xenium Analyzer Shipments
Rapid growth and adoption of Xenium Analyzer demonstrates strength of company's innovation engine, broad commercial reach and operational scale PLEASANTON, Calif. , Aug. 29, 2023 /PRNewswire/ -- 10x G...
10x Genomics Reports Second Quarter 2023 Financial Results
PLEASANTON, Calif. , Aug. 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, ...
10x Genomics to Report Second Quarter 2023 Financial Results on August 3, 2023
PLEASANTON, Calif. , July 13, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the second quarter 2023...
CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine
Data Uncovers New Gene Signature to Help Understand Persistence in CAR T-cells PLEASANTON, Calif. , July 5, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial b...
Red-Hot Quality Opportunities in Genomics
The health care sector is currently undergoing a remarkable transformation. The recent focus on genomics has empowered medical professionals to diagnose patients more objectively and adopt proactive m...
Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe.
10x Genomics Files Two New Lawsuits Requesting Preliminary Injunctions Against NanoString's CosMx Products
Also Files New Suit Against Vizgen's MERSCOPE Products for Patent Infringement PLEASANTON, Calif. , June 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial b...
10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay
Combining tissue profiling with whole transcriptome spatial analysis and high-plex protein co-detection enables a deeper, more holistic understanding of tissue organization PLEASANTON, Calif. , May 24...